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Abstract
Background: Change in the prevalence of raised blood pressure could be due to both
shifts in the entire distribution of blood pressure (representing the combined effects of
public health interventions and secular trends) and changes in its high-blood-pressure
tail (representing successful clinical interventions to control blood pressure in the hyper-
tensive population). Our aim was to quantify the contributions of these two phenomena
to the worldwide trends in the prevalence of raised blood pressure.
Methods: We pooled 1018 population-based studies with blood pressure measurements
on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood
pressure (SBP), mean diastolic blood pressure (DBP) and prevalence of raised blood
pressure by sex and 10-year age group from 20–29 years to 70–79 years in each study,
taking into account complex survey design and survey sample weights, where rele-
vant. We used a linear mixed effect model to quantify the association between (probit-
transformed) prevalence of raised blood pressure and age-group- and sex-specific
mean blood pressure. We calculated the contributions of change in mean SBP and
DBP, and of change in the prevalence-mean association, to the change in prevalence of
raised blood pressure.
Results: In 2005–16, at the same level of population mean SBP and DBP, men and
women in South Asia and in Central Asia, the Middle East and North Africa would have
the highest prevalence of raised blood pressure, and men and women in the high-
income Asia Pacific and high-income Western regions would have the lowest. In most
region-sex-age groups where the prevalence of raised blood pressure declined, one half
or more of the decline was due to the decline in mean blood pressure. Where prevalence
of raised blood pressure has increased, the change was entirely driven by increasing
mean blood pressure, offset partly by the change in the prevalence-mean association.
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Conclusions: Change in mean blood pressure is the main driver of the worldwide change in
the prevalence of raised blood pressure, but change in the high-blood-pressure tail of the
distribution has also contributed to the change in prevalence, especially in older age groups.
Key words: Blood pressure, hypertension, population health, global health, non-communicable disease
Introduction
Raised blood pressure, commonly defined as systolic blood
pressure (SBP)  140 mmHg or diastolic blood pressure
(DBP)  90 mmHg, is used to identify individuals at high
risk of cardiovascular diseases.1–5 Globally, one in four
men and one in five women, totalling 1.13 billion adults,
had raised blood pressure in 2015.6 One of the global non-
communicable disease (NCD) targets adopted by the
World Health Organization (WHO) in 2013 is to reduce
the prevalence of raised blood pressure by 25% compared
with its 2010 level, by 2025.7
The prevalence of raised blood pressure varies substan-
tially across and within regions and countries, with age-
standardized adult prevalence in 2015 ranging from 20%
in the high-income Asia Pacific region to 33% in Central
and Eastern Europe for men, and from 11% in the high-
income Asia Pacific region to 28% in sub-Saharan Africa
for women.6 Prevalence has declined substantially in high-
income regions for decades, and is also declining in some
middle-income regions; it has been stable or has increased
in other low- and middle-income regions.6
Blood pressure is a complex trait, affected by genes,
fetal and early childhood nutrition and growth,8 adiposity
and weight gain,9,10 diet (especially sodium and potassium
intakes),9,11,12 alcohol use,10,13 smoking,14 physical activ-
ity,10,15 air pollution,16 lead,17 noise,18 psychosocial
stress,19 sleep duration20 and the use of blood pressure-
lowering medicines. Changes in some of these factors, for
example increase in body mass index (BMI) and better
nutrition in childhood and adolescence, can shift the entire
population distribution of blood pressure, and hence
change its mean as well as the prevalence of raised blood
pressure. In contrast, the use of antihypertensive medicines
and lifestyle change to reduce blood pressure in those with
elevated levels would reduce the prevalence of raised blood
pressure by acting on the high-blood-pressure tail of the
distribution, and hence change the shape of the distribu-
tion with a relatively small impact on its mean. An import-
ant question that can inform strategies for meeting the
global target and reducing the burden of raised blood pres-
sure, is to what extent regional differences and changes
over time in the prevalence of raised blood pressure are
driven by variations in the mean SBP and DBP versus by
the shape of the distribution. We used a database of
population-based studies with global coverage conducted
over three decades to investigate contributions of popula-
tion mean and high-blood-pressure individuals to world-
wide trends and variations in raised blood pressure.
Methods
Study design
We first used population-based data to estimate the associ-
ation between the prevalence of raised blood pressure,
defined as SBP  140 mmHg or DBP  90 mmHg, and
population mean SBP and DBP among men and women
aged 20 to 79 years in nine regions of the world, from
1985 to 2016. We used a linear mixed effect model to
quantify the association between the prevalence of raised
blood pressure and mean blood pressure. Our statistical
model, described below, allowed the prevalence of raised
Key Messages
• After accounting for the difference in mean blood pressure, there is still a 3–5 percentage-point difference in the
prevalence of raised blood pressure across regions, being highest in South Asia and in Central Asia, the Middle East
and North Africa, and lowest in the high-income Asia Pacific and high-income Western regions.
• Shifts in entire distribution of blood pressure have been the main driver of the change in prevalence of raised blood
pressure.
• There is also a measurable contribution from the change in the high-blood-pressure tail of the distribution, towards
lowering the prevalence of raised blood pressure, especially in older people.
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blood pressure at any level of mean SBP and DBP to differ
by age group, region and time period. We then used the fit-
ted association to estimate the contributions of changes in
the population mean blood pressure versus changes in the
shape of its distribution (represented by how the
prevalence-mean association varied over region and time),
to the changes in the prevalence of raised blood pressure in
different regions.
Data sources
We used data from NCD Risk Factor Collaboration (NCD-
RisC) database, which contains studies that had measured
blood pressure in representative samples of the national
populations or of one or more sub-national regions and com-
munities. NCD-RisC is a worldwide network of health re-
searchers and practitioners whose aim is to document
systematically the worldwide trends and variations in NCD
risk factors. Our methods for identifying and accessing data
sources, and the inclusion and exclusion criteria, are
described in recent publications.6,21–24 In summary, the data-
base was collated through multiple routes for identifying and
accessing data. We accessed publicly available population-
based multi-country and national measurement surveys as
well as the WHO STEPwise approach to Surveillance
(STEPS) surveys. We requested, via WHO and its regional
and country offices, ministries of health and other national
health and statistical agencies to identify and access
population-based surveys. Requests were also sent via the
World Heart Federation to its national partners. We made a
similar request to the co-authors of an earlier pooled analysis
of cardiometabolic risk factors,25–28 and invited them to re-
analyse data from their studies and join NCD-RisC. To iden-
tify major sources not accessed through the above routes, we
searched and reviewed published studies, and invited all eli-
gible studies to join NCD-RisC. Finally, NCD-RisC mem-
bers are periodically asked to review the list of sources from
their country, to suggest additional sources currently not in
the database and to verify that the included data from their
country meet the inclusion criteria as listed in the
Supplementary data (available at IJE online) and that there
are no duplicates. Here, we analysed data collected from
1985 to 2016 on men and women aged 20–79 years, in 10-
year age groups from 20–29 years to 70–79 years.
Statistical methods
We first calculated mean SBP, mean DBP and prevalence
of raised blood pressure for these age groups by sex in each
study, taking into account complex survey design and sur-
vey sample weights, where relevant. We excluded data
points which did not cover complete 10-year age groups,
e.g. those in people aged 25–29 years or 60–64 years, to
avoid bias in the estimated associations. We also excluded
age-sex groups with < 25 participants, because their means
and prevalence have larger uncertainty.
We then estimated the relationship between the preva-
lence of raised blood pressure and mean, using a linear mixed
effect model, shown below in the equation (where e is the
error term), separately by sex. We used probit-transformed
prevalence because it provided a better fit to the data than a
simple linear model or logit transformation. The model
included age group (10-year age groups from 20–29 to
70–79) and the decade when the data were collected
(1985–94, 1995–2004 or 2005–16). We also included inter-
actions between age group and mean blood pressure, be-
tween decade and mean blood pressure, and among these
three terms, which allowed the prevalence-mean association
to vary by age group and over time. We included regional
random intercepts to account for the differences in preva-
lence at any level of mean SBP and DBP by region. The re-
gions, used in previous analyses of cardiometabolic risk
factors,6,21–24 were: Central and Eastern Europe; Central
Asia, the Middle East and North Africa; East and South-east
Asia; high-income Asia Pacific; high-income Western coun-
tries; Latin America and the Caribbean; Oceania; South Asia;
and sub-Saharan Africa. Countries in each region are listed in
Supplementary Table 1 (available as Supplementary data at
IJE online). The models were fitted in statistical software R
version 3.4.2. Goodness of fit of the models was assessed by
conditional R2, which represents the proportion of variance
explained by both fixed and random factors.29
Probit-transformed prevalence of raised blood pressure
¼ b0 þ b1MeanSBP þ b2MeanDBP
þ b3Age groupþ b4Decade
þ b5Age group Decadeþ b6MeanSBP  Age group
þ b7MeanDBP  Age group
þ b8MeanSBP Decadeþ b9MeanDBP Decade
þ b10MeanSBP  Age group Decade
þ b11MeanDBP  Age group Decade
þ Random interceptRegion þ e
We used a simulation approach to account for the un-
certainty in the mean and prevalence data used in fitting
the regression. Specifically, we used 1000 draws from the
uncertainty distributions of each age- and sex-specific in-
put data point (i.e. mean SBP and DBP and prevalence of
raised blood pressure) with uncertainty represented by a
normal distribution for mean SBP and DBP and by a bino-
mial distribution for prevalence of raised blood pressure.
We then fitted a separate regression to each of the 1000
simulated datasets. We sampled 1000 draws from the joint
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distribution of the regression coefficients for each of the
1000 fitted regressions (i.e. 1 000 000 sets of regression co-
efficients). We report the median of the resulting 1 000 000
draws for each coefficient, and their 2.5th and 97.5th per-
centiles as the 95% confidence interval. We also report the
median of conditional R2 from the 1000 fitted regressions.
We used the fitted regressions to quantify how much dif-
ferences across regions, and changes over time in the preva-
lence of raised blood pressure, were driven by differences/
changes in mean SBP and DBP, versus by differences/
changes in the prevalence-mean association. We first used
the age-sex-specific global mean SBP and DBP in 2010
(mid-point of the 2005–16 period) in the fitted associ-
ation, and estimated the prevalence of raised blood pressure
by region. The age-sex-specific mean SBP and DBP values
were taken from a recent comprehensive analysis of world-
wide trends in blood pressure,6 and are listed in the
Supplementary Table 2 (available as Supplementary data at
IJE online). We report the differences between the predicted
regional raised blood pressure prevalence and that of the
world as a whole. These differences measure how much
prevalence would vary across regions—due to geographical
variations in the shape of blood pressure distribution—if
they had the same population mean blood pressure.
We then decomposed total change in prevalence of raised
blood pressure from 1985–94 to 2005–16 into contributions
of change in mean SBP and DBP, change in the shape of
prevalence-mean association and interaction of the two. The
contribution of change in mean was estimated by allowing
mean SBP and DBP for each age, sex and region to change
over time, while keeping the decade variable fixed at
1985–94. The contribution of change in association was esti-
mated by setting mean SBP and DBP to their 1990 levels
(mid-year of 1985–94) for each age, sex and region, and
allowing the decade variable to change. The interaction of
the two factors is the difference between total change in
prevalence and the sum of the above two components. The
three components are schematically shown in Figure 1.
We repeated the above analyses for each of the
1 000 000 sets of regression coefficients. We report the me-
dian of the resulting 1 000 000 estimates as our main result
and their 2.5th and 97.5th percentiles as the 95% confi-
dence interval. All analyses were done separately for men
and women. Results were calculated by 10-year age groups
Figure 1. Schematic diagram for the contributions of change in mean blood pressure and in shape of the blood pressure distribution to the change in
prevalence of raised blood pressure. Each S-shaped curve shows what the prevalence of raised blood pressure would be at different levels of popula-
tion mean for a specific shape of population distribution. A change in mean without a change in the shape of the distribution (Panel A) would move
prevalence along a curve (orange point in Panel D). A change in the shape of the distribution without a change in mean (Panel B) would vertically
move prevalence from one curve to another (blue point in Panel D). The combination (Panel C) would move prevalence from one curve to another, as
well as along the curve (purple point in Panel D). The figure shows the contributions when raised blood pressure is defined based on one blood pres-
sure (either SBP or DBP). The same concept applies when raised blood pressure is defined based on both SBP and DBP.
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and then aggregated into two age bands, 20–49 years and
50–79 years, by taking the weighted average of age-specific
results; weights from the WHO standard population were
used.
Results
Data sources
We used data from 1018 population-based studies with
88 559 656 participants, of whom 86 187 860 were aged
20–79 years, and satisfied the above inclusion criteria
(Supplementary Table 3, available as Supplementary data
at IJE online). A total of 385 studies were from the high-
income Western region, 108 from East and South-east Asia,
107 from Central Asia, the Middle East and North Africa,
106 from Central and Eastern Europe, 83 from sub-
Saharan Africa, 79 from Latin America and the Caribbean,
78 from high-income Asia Pacific, 38 from South Asia and
34 from Oceania. The individual-level data were
summarized into 7910 age-sex-specific pairs of mean of
and prevalence of raised blood pressure. The number of
data sources by country is shown in Figure 2, and a list of
data sources and their characteristics is provided in
Supplementary Table 4 (available as Supplementary data at
IJE online).
Association of prevalence of raised blood
pressure with mean SBP and DBP
The coefficients of the regression models are listed in
Supplementary Tables 5 and 6 (available as Supplementary
data at IJE online). Together, mean SBP and DBP, decade, age
group and region explained most of the variation in the preva-
lence of raised blood pressure, evidenced by the high condi-
tional R2 statistics of 0.918 for women and 0.871 for men.
Changes in prevalence of raised blood pressure
and mean SBP and DBP, by region
In 2005–16, the age-standardized prevalence of raised
blood pressure in people aged 20–49 years ranged from
4% (95% credible interval: 3–6%) in high-income Asia
Pacific to 16% (13–19%) in sub-Saharan Africa in women,
and from 14% (11–17%) in high-income Asia Pacific to
25% (21–30%) in Central and Eastern Europe in
men. In those aged 50–79 years, the range was from 31%
Figure 2. Number of blood pressure data sources from 1985 to 2016 used in the analysis, by country.
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(26–36%) in high-income Asia Pacific to 56% (52–61%)
in sub-Saharan Africa in women, and from 40% (36–43%)
in the high-income Western region to 57% (51–63%) in
Central and Eastern Europe in men.
The prevalence of raised blood pressure decreased sub-
stantially from 1985–94 to 2005–16 in the two high-
income regions and Central and Eastern Europe in both
men and women across all ages (Figure 3).6 It also
decreased in Latin America and the Caribbean, and in
Central Asia, the Middle East and North Africa, and mar-
ginally in men in sub-Saharan Africa. Over the same
period, mean SBP and mean DBP decreased in these
regions and sexes, except in men in sub-Saharan Africa,
whose mean SBP and DBP increased, and in men in
Central Asia, the Middle East and North Africa, whose
mean SBP and DBP were unchanged. The prevalence of
raised blood pressure and mean SBP and DBP increased in
Oceania and South Asia.
Contributions of mean and shape of blood
pressure distribution to regional variations in
raised blood pressure
Although in 2005–16 the ranking of regions in terms of
prevalence of raised blood pressure was largely the same as
Figure 3. Changes in prevalence of raised blood pressure, mean SBP and mean DBP from 1985–94 to 2005–16, by region, sex and age group.
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the ranking of the mean, especially for women, inter-
region differences in prevalence were not entirely due to
those of mean blood pressure. Rather, some regions had an
excess prevalence compared with what would be expected
based on their mean, and others a lower prevalence com-
pared with what would be expected based on their mean.
At the same level of population mean SBP and DBP as that
of the world as a whole, men and women in South Asia
and in Central Asia, the Middle East and North Africa
would have the highest prevalence of raised blood pres-
sure, about 1–2 percentage points higher than the
world average in different age groups (Figure 4). In con-
trast, at the same level of population mean SBP and DBP as
that of the world as a whole, high-income Asia Pacific
would have the lowest prevalence, followed by the high-
income Western region, with prevalence about 1–3
percentage points lower than the world average across dif-
ferent age and sex groups, especially among women. The
Figure 4. Regional differences in prevalence of raised blood pressure among men and women aged 20–49 years and 50–79 years in 2005–16 if every
region had the same mean SBP and DBP, equal to the global age-sex-specific mean in 2010. The points show the central estimates and the bars their
95% confidence intervals.
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ordering of regions in terms of excess prevalence was simi-
lar between men and women, except for men in Central
and Eastern Europe whose ranking in terms of excess
prevalence was worse than that of women in the same
region.
Contributions of mean and shape of blood pressure
distribution to trends in raised blood pressure
In most regions where sex and age groups experienced a
decline in the prevalence of raised blood pressure, the de-
cline in mean blood pressure was the main driver of the de-
cline in prevalence (Figure 5). The main exceptions to this
distributional shift were men in sub-Saharan Africa and in
Central Asia, the Middle East and North Africa, whose
mean blood pressure increased or remained unchanged
while prevalence declined slightly. Further, in men in Latin
America and the Caribbean and in Central and Eastern
Europe, change in prevalence-mean association contrib-
uted marginally more to prevalence decline than did the
decline in mean blood pressure. Elsewhere, the decline in
mean blood pressure accounted for 60% or more of the de-
cline in the prevalence of raised blood pressure, with a
larger contribution where mean blood pressure declined
more, typically in high-income regions. Change in the
prevalence-mean association, which represents change in
the high-blood-pressure tail of the distribution, was re-
sponsible for the majority of the remainder of change in
prevalence, and for its entirety among men in sub-Saharan
Africa and in Central Asia, the Middle East and North
Africa. The contribution of change in prevalence-mean as-
sociation was larger in those aged 50–79 years than in
those aged 20–49 years in most regions, especially for
women.
The prevalence of raised blood pressure increased
among men and women in Oceania and South Asia, and
among women in sub-Saharan Africa and men in East and
South-east Asia. The increase was driven entirely by rise in
mean blood pressure, offset partly by the change in the
prevalence-mean association. Prevalence of raised blood
pressure remained largely unchanged among women in
East and South-east Asia, due to opposing effects of
Figure 5. Contributions of change in mean blood pressure, change in prevalence-mean association, and the interaction of the two, to change in preva-
lence of raised blood pressure from 1985–94 to 2005–16 by region, sex and age group.
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increasing mean and the decrease brought by the changes
in prevalence-mean association.
Discussion
We found that the trends and geographical variations in
the prevalence of raised blood pressure are largely driven
by shifts in the distribution of blood pressure in whole
populations, rather than by the shape of the distribution.
There was nonetheless an important contribution from
having fewer high-blood-pressure individuals at the same
level of population mean SBP and DBP over time, espe-
cially in older age groups.
Rose and Day30 and Laaser et al.31 used data from the
Intersalt Study and from population-based studies in
Germany, respectively, and found a strong association be-
tween prevalence of raised blood pressure and its mean, as
we did, but neither analysis had sufficient data to quantify
how the association varied in relation to age, time period or
region as was done here. An analysis of data from the multi-
country MONICA Project32 found that the upper percentiles
of blood pressure distribution changed as much as its mean
in some communities, and by a larger amount in others. The
authors concluded that the decline in blood pressure is
mostly a population phenomenon but there was no detailed
quantification of the contribution, especially in relation to
age, time period or region as was done here with substan-
tially more data. Downward shifts in the whole blood pres-
sure distribution over time have also been reported in a few
high-income countries,33–40 with some studies also finding a
larger decline in the upper tail than in the mean of the blood
pressure distribution, which is consistent with our results.
The strengths of our study include presenting the first
global analysis of how much population mean and high-
blood-pressure individuals have contributed to worldwide
trends and variations in raised blood pressure, using a large
global database with data from different regions and over
time, and using methods that allowed the prevalence-mean
association to vary by sex, age group, time period and re-
gion. Despite using the most comprehensive global collec-
tion of population-based studies to date, some regions had
limited data, especially early in our analysis period. Further,
there have been changes over time in devices used for meas-
uring blood pressure in health surveys, with standard mer-
cury sphygmomanometers replaced by random-zero
sphygmomanometers and more recently digital oscillometric
devices. These changes are unlikely to have affected our re-
gional comparisons, and would only affect prevalence-mean
association over time if they had differential effects at high
versus low blood pressure.
Although we found that changes in the prevalence
of raised blood pressure have been mostly due to
whole-distribution shifts, the behavioural, nutritional and
environmental drivers of this shift remain uncertain. In
high-income countries, the decline in blood pressure has
occurred despite the rise in BMI,21 which is an established
risk factor for high blood pressure, but how the concurrent
and at times larger rise in BMI in low- and middle-income
countries may be affecting blood pressure is unclear. Salt in-
take has declined in China41 and possibly in some high-
income countries,42–44 but has not changed in other coun-
tries where blood pressure has declined.45–49 Similarly,
prevalence of smoking has declined in most high-income
countries and in some middle-income countries but remains
high or is increasing in other low- and middle-income re-
gions.50 Alcohol consumption has also had mixed trends
across countries and regions.51 Other potential population-
wide drivers of the decline in mean blood pressure which
tend to improve with social and economic development in-
clude year-round availability of fruits and vegetables, which
might increase the amount and regularity of their consump-
tion;52 central heating at home and work which would
lower winter blood pressure;53–55 and improvements in
early childhood and adolescent nutrition, as seen in greater
height in successive birth cohorts when they reach adult-
hood.23 A role for such distal determinants with life course
impacts is strengthened by the fact that blood pressure is
also decreasing in adolescents in high-income countries and
possibly some middle-income countries.56–60
Whereas these determinants act to lower mean blood
pressure, better developed health systems are more effect-
ive in identifying and treating high-blood-pressure indi-
viduals, which would change the tail of the distribution
without a major impact on its mean. The role of treat-
ment in reducing the prevalence of high blood pressure
has become increasingly important as clinical guidelines
have lowered the threshold for diagnosing and treating
hypertension, e.g. from having an SBP of 160 mmHg or
DBP of 95 mmHg in the 1970s61 to an SBP of 140 mmHg
or DBP of 90 mmHg,4,62 and to an SBP of 130 mmHg or
DBP of 80 mmHg in the newly released ACC/AHA guide-
lines.3 Over time, regional and international guidelines
for diagnosis and treatment of hypertension, which are
evaluated as cost-effective,2,63,64 have been developed
and a larger share of people with raised blood pressure
are treated in high-income countries33,65–72 and in some
middle-income countries.73–78 Nonetheless, treatment
coverage and effectiveness remain low, especially in low-
income settings.79,80 Further, there have been improve-
ments in effectiveness of treatment over time, leading to
better control of those with hypertension. It may also be
the case that changes in some risk factors, e.g. lower salt
intake, have larger benefits for people whose blood pres-
sure is high compared with those with low blood
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pressure,11 hence changing the high-blood-pressure tail of
the distribution as well as its mean.
Our results demonstrate that changes in blood pressure
both at the population and at the individual level have
contributed to lowering raised blood pressure. What fac-
tors have spurred the former over the past few decades,
however, remain largely unclear, and may be related to
societal changes in nutrition, housing and health systems
arising from social and economic development and
technological progress. They also demonstrate the need
for data that go beyond identifying the causes of low or
high blood pressure, but also help measure how these fac-
tors change over time in worldwide populations. Learning
about these factors would inform programmes that can
help reverse the rise in the prevalence of raised blood
pressure or accelerate its decline in low- and middle-
income nations, where prevalence remains the highest,
more effectively.
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Medical Center Rotterdam, The Netherlands)*; Gyulli
Kazakbaeva (Ufa Eye Research Institute, Russia)*;
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University, Belgium)*; Tai Hing Lam (University of
Hong Kong, China)*; Orlando Landrove (Ministerio
de Salud Pu´blica, Cuba)*; Vera Lanska (Institute for
Clinical and Experimental Medicine, Czech
Republic)*; Georg Lappas (Sahlgrenska Academy,
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Lauren Lissner (University of Gothenburg, Sweden)*;
Mieczyslaw Litwin (Children’s Memorial Health
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UK)*; Rachael M McLean (University of Otago, New
Zealand)*; Scott B McLean (Statistics Canada,
Canada)*; Breige A McNulty (University College
883e International Journal of Epidemiology, 2018, Vol. 47, No. 3
D
ow
nloaded from
 https://academ
ic.oup.com
/ije/article-abstract/47/3/872/4944405 by guest on 18 D
ecem
ber 2019
Dublin, Ireland)*; Sounnia Mediene-Benchekor
(University of Oran 1, Algeria)*; Jurate Medzioniene
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Tartu, Estonia)*; Jody C Miller (University of Otago,
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(Pontificia Universidad Cato´lica de Chile, Chile)*; J
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Pe´cs, Hungary)*; Amirabbas Momenan (Shahid
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Singapore, Singapore)*; Vinay B Nangia (Suraj Eye
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